Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LLP2A-alendronate (University of California, Davis)
- Development stage
- Phase 1
- Lead developer
- University of California, Davis
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
LLP2A-alendronate is a bone-targeted peptidomimetic conjugate designed to promote bone formation and repair by recruiting mesenchymal stem cells (MSCs) directly to the bone surface. The molecule consists of two functional moieties: **alendronate**, a bisphosphonate that provides high affinity for the bone mineral hydroxyapatite, and **LLP2A**, a high-affinity peptidomimetic ligand that specifically targets the active conformation of **integrin alpha-4 beta-1** (VLA-4) expressed on MSCs. By anchoring to the bone surface via the alendronate component, the conjugate creates a localized concentration of LLP2A that acts as a "homing beacon" for circulating or resident MSCs. Once recruited, these stem cells differentiate into osteoblasts, thereby increasing bone mass and strength. This approach is being investigated as an anabolic (bone-building) therapy for conditions characterized by bone loss or poor healing, such as osteoporosis and osteonecrosis.
- Other names
- LLP2A-alendronate conjugateLLP-2A-alendronate conjugateLLP 2A-alendronate conjugateLLP2A-bisphosphonate conjugateLLP-2A-bisphosphonate conjugateLLP 2A-bisphosphonate conjugate
02
Targets
FDPS (Farnesyl pyrophosphate synthase)α4β1 (Integrin α4β1)
Beyond the preview
Go deeper on LLP2A-alendronate (University of California, Davis).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LLP2A-alendronate (University of California, Davis).